Latest Research And Development News

Telix Pharmaceuticals has completed a strategic acquisition of ImaginAb, gaining next-generation therapeutic assets and a novel biologics platform to expand its oncology pipeline and R&D capabilities.

PainChek Ltd reports robust growth with 100,000 contracted licences globally and positive FDA clearance progress, alongside a promising launch of its Infant App targeting a vast new market.

Optiscan Imaging Ltd has secured a $1.775 million R&D tax refund for FY24, more than doubling last year’s amount thanks to expanded claims on overseas research. The boost will fund ongoing development of its cutting-edge confocal laser endomicroscopy technology.

Neurotech International has secured a $2.44 million R&D tax incentive refund, strengthening its cash position as it advances clinical trials for paediatric neurological disorders and prepares for regulatory submissions in FY2025.

Strategic Elements Ltd reports a robust cash position and progress across its portfolio of early-stage ventures, including the promising Energy Ink™ technology and autonomous vehicle applications in mining.

Green Critical Minerals has made significant strides in commercialising its Very High-Density (VHD) Graphite technology, achieving exceptional pilot plant results and positioning itself at the forefront of clean energy and electronics markets.

Avecho Biotechnology progresses its Phase III clinical trial for a TPM®-enhanced CBD insomnia capsule, expands patient recruitment, and completes a major manufacturing campaign for its U.S. partner Ashland.

BlinkLab has launched its pivotal FDA registrational study for its AI-driven autism diagnostic app, BlinkLab Dx 1, following positive FDA feedback and promising preliminary results.

Impact Minerals reports a maiden Measured Resource at its Lake Hope High Purity Alumina Project and secures $2.87 million in government funding to accelerate pilot plant development, while progressing exploration and IPO plans for other assets.

Zelira Therapeutics has secured a fourth funding tranche of US$681,000, advancing its HOPE® Autism Spectrum Disorder FDA trial process and bringing total funding to US$3.25 million. The company is progressing clinical validation and product development, including the transformation of Zenivol® into a capsule formulation.

Cycliq Group Ltd reports a robust Q2 FY2025 with a 15% rise in cash receipts to $1.92 million and strategic leadership appointments aimed at accelerating growth.

Cycliq Group Limited reported a robust net operating cash flow of $964,000 for the December 2024 quarter, bolstered by government grants and disciplined cost management. The company ended the period with a healthy cash balance of $1.12 million, signaling improved liquidity.